It is very uncertain whether infliximab 5 mg/kg changes clinical remission at week 4 compared with infliximab 20 mg/kg (very low certainty).
It is very uncertain whether infliximab 5 mg/kg changes clinical remission defined as CDAI < 150 at week 4 compared with infliximab 10 mg/kg (very low certainty).
It is very uncertain whether infliximab 5 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with infliximab 10 mg/kg (very low certainty).
Infliximab 5 mg/kg showed no clear difference in clinical remission defined as CDAI < 150 at week 6 compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
Infliximab 5 mg/kg may leads to higher clinical remission at week 26 compared with purine analogues (low certainty).
It is very uncertain whether infliximab 10 mg/kg changes clinical remission defined as CDAI < 150 at week 4 compared with infliximab 20 mg/kg (very low certainty).
Infliximab 5 mg/kg and purine analogues probably leads to higher clinical remission as defined by the studies at weeks 24–26 compared with purine analogues alone (moderate certainty).
Infliximab 5–10 mg/kg may leads to higher clinical remission defined as CDAI < 150 at week 4 compared with placebo (low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in failure to induce clinical remission at week 10 compared with placebo and two infusions of infliximab (moderate certainty).
It is very uncertain whether infliximab 5–10 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with placebo (very low certainty).